ImmunotherapyPreventative VaccinesGene Therapy

Etubics

Welcome to Etubics

Etubics Corporation is a Seattle based biopharmaceutical company developing targeted immunotherapies and vaccine products for a wide range of resilient diseases. Etubics patent-protected technology has been proven to be safer, more efficient and more effective than current vectored vaccines and gene delivery platforms.

We specialize in developing innovative immunotherapies and vaccines utilizing our exclusive next-generation viral vector gene delivery technology and our patented manufacturing cell line, together the Etubics Platform.

The Etubics Platform delivers a long lasting “active” immune response against diseases and induces both cell mediated immunity and antibody. The Etubics Platform provides the following capabilities:

  • Utilization of boosting
  • Enhanced CMI response
  • No unwanted viral replication in the body
  • Treatment of multiple diseases in the same patient
  • Convenient subcutaneous injection
Next Generation Vaccines What’s New

Etubics is developing innovative immunotherapies and vaccines, utilizing our proprietary gene delivery platform and our patented human E.C7 human cell line, together the Etubics Platform.

The Etubics Platform provides the following capabilities: a long lasting “active” immune response against diseases and induces both cell mediated immunity and antibody.

Etubics Corporation has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute, a part of the National Institutes of Health, to investigate a multi-targeted immunotherapy approach containing three tumor-associated antigens including ETBX-011. These three antigens are highly expressed in various human carcinomas and the ability to simultaneously target all three could be of significant clinical benefit in terms of overall survival of cancer patients.

Find out more about our Technology

Etubics Corporation is pleased to announce our participation in the National Immunotherapy Coalition (NIC) and The Cancer MoonShoot 2020 program.  As a participant in the NIC, we will be joining multinational pharmaceutical, biotechnology and insurance companies, academic cancer research centers and oncologists in an effort to collaborate on the research and development of combination immunotherapy treatments.  The NIC and The Cancer MoonShot 2020 program will focus on designing, initiating and completing randomized clinical trials at all stages of cancer in as many as 20,000 patients by the year 2020 with the goal of accelerating the potential of cancer immunotherapies as the new standard of treatment for patients with cancer.

For more information regarding the NIC and The Cancer MoonShot 2020 program, visit: http://www.cancermoonshot2020.org/

We are excited to be chosen to participate in this program.

vaccine2

Last Updated: February 2016